These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 34040756)

  • 1. Corrigendum to: Tranexamic acid use in a patient with sickle cell disease undergoing posterior scoliosis correction surgery: safely mitigating bleeding and vaso-occlusive crises.
    Newall M; Hamdan TA; Ajayi B; Weil S; Bishop T; Lui DF
    J Surg Case Rep; 2021 May; 2021(5):rjab229. PubMed ID: 34040756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tranexamic acid use in a patient with sickle cell disease undergoing posterior scoliosis correction surgery: safely mitigating bleeding and vaso-occlusive crises.
    Newall M; Hamdan TA; Lui DF; Ajayi B; Bishop T; Weil S
    J Surg Case Rep; 2021 Jan; 2021(1):rjaa559. PubMed ID: 33542809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-molecular-weight heparins for managing vaso-occlusive crises in people with sickle cell disease.
    van Zuuren EJ; Fedorowicz Z
    Cochrane Database Syst Rev; 2013 Jun; (6):CD010155. PubMed ID: 23760785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Magnetic Resonance Imaging Assessment of Kidney Oxygenation and Perfusion During Sickle Cell Vaso-occlusive Crises.
    Deux JF; Audard V; Brugières P; Habibi A; Manea EM; Guillaud-Danis C; Godeau B; Galactéros F; Stehlé T; Lang P; Grimbert P; Audureau E; Rahmouni A; Bartolucci P
    Am J Kidney Dis; 2017 Jan; 69(1):51-59. PubMed ID: 27663041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urinary cross-linked carboxyterminal telopeptide, a bone resorption marker, decreases after vaso-occlusive crises in adults with sickle cell disease.
    Adesina OO; Jenkins IC; Wu QV; Fung EB; Narla RR; Lipkin EW; Mahajan K; Konkle BA; Kruse-Jarres R
    Blood Cells Mol Dis; 2020 Feb; 80():102369. PubMed ID: 31677454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exacerbation of oxidative stress during sickle vaso-occlusive crisis is associated with decreased anti-band 3 autoantibodies rate and increased red blood cell-derived microparticle level: a prospective study.
    Hierso R; Lemonne N; Villaescusa R; Lalanne-Mistrih ML; Charlot K; Etienne-Julan M; Tressières B; Lamarre Y; Tarer V; Garnier Y; Hernandez AA; Ferracci S; Connes P; Romana M; Hardy-Dessources MD
    Br J Haematol; 2017 Mar; 176(5):805-813. PubMed ID: 27984639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the Coagulation Profile of Adolescent Idiopathic Scoliosis Patients Undergoing Posterior Spinal Fusion With and Without Tranexamic Acid.
    Bosch P; Kenkre TS; Soliman D; Londino JA; Novak NE
    Spine Deform; 2019 Nov; 7(6):910-916. PubMed ID: 31732001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erratum: Field JJ, Majerus E, Gordeuk VR, et al. Randomized phase 2 trial of regadenoson for treatment of acute vaso-occlusive crises in sickle cell disease.
    Blood Adv; 2017 Oct; 1(23):2058. PubMed ID: 29297515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sevuparin for the treatment of acute pain crisis in patients with sickle cell disease: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
    Biemond BJ; Tombak A; Kilinc Y; Al-Khabori M; Abboud M; Nafea M; Inati A; Wali Y; Kristensen J; Kowalski J; Donnelly E; Ohd J;
    Lancet Haematol; 2021 May; 8(5):e334-e343. PubMed ID: 33894169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary hyperparathyroidism mimicking vaso-occlusive crises in sickle cell disease.
    Krishnamoorthy P; Alyaarubi S; Abish S; Gale M; Albuquerque P; Jabado N
    Pediatrics; 2006 Aug; 118(2):e537-9. PubMed ID: 16882790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Types of crises in sickle cell disease patients presenting at the haematology day care unit (HDCU), University College Hospital (UCH), Ibadan.
    Olabode JO; Shokunbi WA
    West Afr J Med; 2006; 25(4):284-8. PubMed ID: 17402517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Multinational Trial of Prasugrel for Sickle Cell Vaso-Occlusive Events.
    Heeney MM; Hoppe CC; Abboud MR; Inusa B; Kanter J; Ogutu B; Brown PB; Heath LE; Jakubowski JA; Zhou C; Zamoryakhin D; Agbenyega T; Colombatti R; Hassab HM; Nduba VN; Oyieko JN; Robitaille N; Segbefia CI; Rees DC;
    N Engl J Med; 2016 Feb; 374(7):625-35. PubMed ID: 26644172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidural analgesia in the management of severe vaso-occlusive sickle cell crisis.
    Yaster M; Tobin JR; Billett C; Casella JF; Dover G
    Pediatrics; 1994 Feb; 93(2):310-5. PubMed ID: 8121746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design of the DOVE (Determining Effects of Platelet Inhibition on Vaso-Occlusive Events) trial: A global Phase 3 double-blind, randomized, placebo-controlled, multicenter study of the efficacy and safety of prasugrel in pediatric patients with sickle cell anemia utilizing a dose titration strategy.
    Hoppe CC; Styles L; Heath LE; Zhou C; Jakubowski JA; Winters KJ; Brown PB; Rees DC; Heeney MM
    Pediatr Blood Cancer; 2016 Feb; 63(2):299-305. PubMed ID: 26402148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The presentation and management of the acute abdomen in the patient with sickle-cell anemia.
    Baumgartner F; Klein S
    Am Surg; 1989 Nov; 55(11):660-4. PubMed ID: 2817619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of tranexamic acid for controlling bleeding in thoracolumbar scoliosis surgery with posterior instrumentation.
    da Rocha VM; de Barros AG; Naves CD; Gomes NL; Lobo JC; Villela Schettino LC; da Silva LE
    Rev Bras Ortop; 2015; 50(2):226-31. PubMed ID: 26229921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating platelet aggregates in sickle cell disease patients with and without vaso-occlusion.
    Mehta P; Mehta J
    Stroke; 1979; 10(4):464-6. PubMed ID: 505486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Electronic Health Record-Embedded Individualized Pain Plans for Emergency Department Treatment of Vaso-occlusive Episodes in Adults With Sickle Cell Disease: Protocol for a Preimplementation and Postimplementation Study.
    Luo L; King AA; Carroll Y; Baumann AA; Brambilla D; Carpenter CR; Colla J; Gibson RW; Gollan S; Hall G; Klesges L; Kutlar A; Lyon M; Melvin CL; Norell S; Mueller M; Potter MB; Richesson R; Richardson LD; Ryan G; Siewny L; Treadwell M; Zun L; Armstrong-Brown J; Cox L; Tanabe P
    JMIR Res Protoc; 2021 Apr; 10(4):e24818. PubMed ID: 33861209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urinary creatine: biochemical indicator for evaluation of sickle cell crises.
    Beyer C; Statius van Eps LW; Kastelein JJ; Brandjes DP; Mairuhu WM; van den Ende A
    Clin Chem; 1985 Jul; 31(7):1232-4. PubMed ID: 4006197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fragment D-dimer levels: an objective marker of vaso-occlusive crisis and other complications of sickle cell disease.
    Devine DV; Kinney TR; Thomas PF; Rosse WF; Greenberg CS
    Blood; 1986 Jul; 68(1):317-9. PubMed ID: 3719103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.